Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer

NCT01325428 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT01325428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01325428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2011
Completion date
November 30, 2014
Enrollment
26 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms